# Study of Sacituzumab Govitecan in Patients With Solid Tumor

> **NCT05119907** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Gilead Sciences** · enrollment: 53 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Sacituzumab Govitecan-hziy

## Key facts

- **NCT ID:** NCT05119907
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-12
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05119907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05119907, "Study of Sacituzumab Govitecan in Patients With Solid Tumor". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05119907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*